our alliances

"This important alliance with GSK will provide us with access to significant capital in the near and long term to support the ongoing development of each of these programs, as well as the ability to continue to discover and bring forward multiple new compounds targeting the chemokine system."

Thomas J. Schall, Ph.D.
President and CEO of ChemoCentryx
ChemoCentryx, Inc.